litlas
ログインアカウント作成

Hossein Borghaei

2009–2025 年に発表

114
論文数
29,005
被引用数
64
h 指数
105
i10 指数

被引用数

Hossein Borghaei の年別被引用数1976 年: 被引用 1 件1990 年: 被引用 1 件2000 年: 被引用 1 件2001 年: 被引用 2 件2003 年: 被引用 1 件2004 年: 被引用 1 件2005 年: 被引用 1 件2006 年: 被引用 1 件2007 年: 被引用 2 件2008 年: 被引用 1 件2009 年: 被引用 3 件2010 年: 被引用 7 件2011 年: 被引用 19 件2012 年: 被引用 18 件2013 年: 被引用 35 件2014 年: 被引用 75 件2015 年: 被引用 109 件2016 年: 被引用 145 件2017 年: 被引用 251 件2018 年: 被引用 490 件2019 年: 被引用 1,586 件2020 年: 被引用 2,020 件2021 年: 被引用 1,939 件2022 年: 被引用 1,525 件2023 年: 被引用 1,124 件2024 年: 被引用 1,683 件2025 年: 被引用 896 件2026 年: 被引用 15 件1977〜1989 年は被引用が無いため表示していません1991〜1999 年は被引用が無いため表示していません2002 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,463 件、この内訳の 23.8%中国: 引用元論文 2,636 件、この内訳の 18.1%イタリア: 引用元論文 785 件、この内訳の 5.4%日本: 引用元論文 660 件、この内訳の 4.5%フランス: 引用元論文 655 件、この内訳の 4.5%イギリス: 引用元論文 627 件、この内訳の 4.3%ドイツ: 引用元論文 600 件、この内訳の 4.1%スペイン: 引用元論文 538 件、この内訳の 3.7%カナダ: 引用元論文 424 件、この内訳の 2.9%韓国: 引用元論文 381 件、この内訳の 2.6%オーストラリア: 引用元論文 352 件、この内訳の 2.4%スイス: 引用元論文 327 件、この内訳の 2.3%
0%23.8%その他 21.4%

機関

分野

  • Medicine79.1%
  • Biochemistry, Genetics and Molecular Biology13.9%
  • Immunology and Microbiology4.1%
  • Engineering0.8%
  • Neuroscience0.4%
  • Computer Science0.3%
  • その他1.4%

トピック

  • Cancer Immunotherapy and Biomarkers18.4%
  • Lung Cancer Treatments and Mutations9%
  • Lung Cancer Research Studies6%
  • Immunotherapy and Immune Responses4.6%
  • Lung Cancer Diagnosis and Treatment4%
  • CAR-T cell therapy research3.6%
  • その他54.4%

共著者

全論文

検索で開く
  1. Sotorasib for Lung Cancers with KRAS p.G12C Mutation

    著者: Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy Price, Gerald S. Falchook, Jürgen Wolf, Antoîne Italiano, Martin Schüler, Hossein Borghaei, Fabrice Barlési, Terufumi Kato, Alessandra Curioni‐Fontecedro, Adrian G. Sacher, Alexander I. Spira, Suresh S. Ramalingam, Toshiaki Takahashi, Benjamin Besse, Abraham Anderson, Agnes Ang, Qui Tran, Omar Mather, Haby Henary, Gataree Ngarmchamnanrith, Gregory Friberg, Vamsidhar Velcheti, Ramaswamy Govindan - New England Journal of Medicine 2021 被引用: 1,769

  2. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

    著者: Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro, Bogdan Żurawski, Sang‐We Kim, Enric Carcereny, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Solange Peters, Konstantinos Syrigos, Fabrice Barlési, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Sridhar K. Rabindran, Ravi S. Kasinathan, Faith E. Nathan, Suresh S. Ramalingam - New England Journal of Medicine 2019 被引用: 2,835

  3. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

    著者: Myung‐Ju Ahn, Byoung Chul Cho, Enriqueta Felip, Ippokratis Korantzis, Kadoaki Ohashi, Margarita Majem, Óscar Juan, Sabin Handzhiev, Hiroki Izumi, Jong Seok Lee, Rafał Dziadziuszko, Jürgen Wolf, Fiona Blackhall, Martin Reck, Jean Bustamante Alvarez, Horst-Dieter Hummel, Anne‐Marie C. Dingemans, Jacob Sands, Hiroaki Akamatsu, Taofeek K. Owonikoko, Suresh S. Ramalingam, Hossein Borghaei, Melissa L. Johnson, Shuang Huang, Sujoy Mukherjee, Mukul Minocha, Tony Jiang, Pablo Martínez, Erik S. Anderson, Luis Paz‐Ares - New England Journal of Medicine 2023 被引用: 482

  4. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    著者: Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak A. Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie R. Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Chang Han, Joseph D. Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith E. Nathan, Luis Paz‐Ares - New England Journal of Medicine 2018 被引用: 3,137

  5. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    著者: David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski - New England Journal of Medicine 2017 被引用: 2,575

  6. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

    著者: Julie R. Brahmer, Jong-Seok Lee, Tudor–Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, László Urbán, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Adam Płużański, Jacobus A. Burgers, Mauricio Mahave, Samreen Ahmed, Adam J. Schoenfeld, Luis Paz‐Ares, Martin Reck, Hossein Borghaei, Kenneth J. O’Byrne, Ravi G. Gupta, Judith Bushong, Li Li, Steven I. Blum, Laura J. Eccles, Suresh S. Ramalingam - Journal of Clinical Oncology 2022 被引用: 381

  7. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

    著者: Luis Paz‐Ares, Stéphane Champiat, W. Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa L. Johnson, Neeltje Steeghs, Fiona Blackhall, Afshin Dowlati, Noemı́ Reguart, Tatsuya Yoshida, Kai He, Shirish M. Gadgeel, Enriqueta Felip, Yiran Zhang, Amrita Pati, Mukul Minocha, Sujoy Mukherjee, Amanda Goldrick, Dirk Nagorsen, Nooshin Hashemi Sadraei, Taofeek K. Owonikoko - Journal of Clinical Oncology 2023 被引用: 294

  8. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

    著者: Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Laura Q.M. Chow, Marco Angelo Burgio, Javier de Castro, Adam Płużański, Óscar Arrieta, Osvaldo Arén Frontera, Rita Chiari, Charles Butts, Joanna Wójcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip, M. Alonso Garcìa, David Waterhouse, Manuel Dómine, Fabrice Barlési, Scott Antonia, M Wohlleber, David E. Gerber, Grzegorz Czyżewicz, David R. Spigel, Lucio Crinò, Wilfried Eberhardt, Ang Li, S. Marimuthu, Julie R. Brahmer - Journal of Clinical Oncology 2021 被引用: 661

  9. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

    著者: Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi, Ben Creelan, Francisco Sánchez-Vega, Arun Ahuja, Ai Ni, Jacki B. Novik, Levi Mangarin, Mohsen Abu-Akeel, Cailian Liu, Jennifer L. Sauter, Natasha Rekhtman, Eliza Chang, Margaret K. Callahan, Jamie E. Chaft, Martin H. Voss, Megan Tenet, Xuemei Li, Kelly L. Covello, Andrea Renninger, Patrik Vitazka, William J. Geese, Hossein Borghaei, Charles M. Rudin, Scott Antonia, Charles Swanton, Jeff Hammerbacher, Taha Merghoub, Nicholas McGranahan, Alexandra Snyder, Jedd D. Wolchok - Cancer Cell 2018 被引用: 1,175

  10. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    著者: Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Płużański, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Żurawski, Aurelia Alexandru, A. Vergnenègre, Judith Raimbourg, Kynan Feeney, Sang‐We Kim, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck - Journal of Thoracic Oncology 2021 被引用: 322

  11. First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

    著者: Neal Ready, Matthew D. Hellmann, Mark M. Awad, Gregory A. Otterson, Martin Gutierrez, Justin F. Gainor, Hossein Borghaei, Jacques Jolivet, Leora Horn, Mihaela Mates, Julie R. Brahmer, Ian Rabinowitz, Pavan S. Reddy, Jason Chesney, James Michael Orcutt, David R. Spigel, Martin Reck, Kenneth J. O’Byrne, Luis Paz‐Ares, Wenhua Hu, Kim E. Zerba, Xuemei Li, Brian Lestini, William J. Geese, Joseph D. Szustakowski, George Green, Chang Han, Suresh S. Ramalingam - Journal of Clinical Oncology 2019 被引用: 596

  12. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

    著者: Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz‐Ares, Adam Płużański, Karen L. Reckamp, Marco Angelo Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlési, Scott Antonia, Óscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer A. Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood‐Chirchir, Diane Healey, Julie R. Brahmer, Wilfried Eberhardt - Journal of Clinical Oncology 2017 被引用: 875

  13. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    著者: Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, Vassiliki A. Papadimitrakopoulou, Amita Patnaik, Steven Powell, Ryan D. Gentzler, Renato Martins, James Stevenson, Shadia I. Jalal, Amit Panwalkar, James Chih‐Hsin Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Joseph Fiore, Yang Ge, Harry Raftopoulos, Leena Gandhi - The Lancet Oncology 2016 被引用: 1,392

  14. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

    著者: Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, Scott Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal Ready, David E. Gerber, Laura Q.M. Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, William J. Geese, Shruti Agrawal, Tina C. Young, Xuemei Li, Scott Antonia - The Lancet Oncology 2016 被引用: 961

  15. Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

    著者: Julia Judd, Nagla Abdel Karim, Hina Khan, Abdul Rafeh Naqash, Yasmine Baca, Joanne Xiu, Ari M. VanderWalde, Hirva Mamdani, Luis E. Raez, Misako Nagasaka, Sachin Gopalkrishna Pai, Mark A. Socinski, Jorge J. Nieva, Chul Kim, Antoinette J. Wozniak, Chukwuemeka Ikpeazu, Gilberto de Lima Lopes, Alexander I. Spira, W. Michael Korn, Edward S. Kim, Stephen V. Liu, Hossein Borghaei - Molecular Cancer Therapeutics 2021 被引用: 186

  16. The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

    著者: Hermann Einsele, Hossein Borghaei, Robert Z. Orlowski, Marion Subklewe, Gail J. Roboz, Gerhard Zugmaier, Peter Kufer, Karim Iskander, Hagop M. Kantarjian - Cancer 2020 被引用: 231

  17. Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)

    著者: J. Nicholas Bodor, Yanis Boumber, Hossein Borghaei - Cancer 2019 被引用: 349

  18. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    著者: Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin, Craig H. Reynolds, Willemijn S.M.E. Theelen, Ivor Percent, V. Gutiérrez Calderón, Melissa L. Johnson, Anne Madroszyk, Edward B. Garon, Kai He, David Planchard, Martin Reck, Sanjay Popat, Roy S. Herbst, Ticiana Leal, Ronald Shazer, Xin Yan, Richard Harrigan, Solange Peters, Isam Abdel-Karim, Mahmoud Abdelsalam, Alfredo Addeo, Carlos Aguado, Patrick Alexander, Jürgen Alt, Georges Azzi, Rama Balaraman, Bonne Biesma, Fiona Blackhall, Sabine Bohnet, Ekaterini Boleti, Hossein Borghaei, Penelope A. Bradbury, Matteo Brighenti, Nicholas Campbell, Toby Campbell, Jean-Luc Canon, Federico Cappuzzo, Enric Carcereny Costa, Luigi Cavanna, Jeremy Cetnar, Antonio Chella, C. Chouaïd, Daniel C. Christoph, J. Cortés Castán, Shaker R. Dakhil, F.J. de Castro Carpeño, Filippo de Marinis, Angelo Delmonte, Ingel Demedts, Wim Demey, Joyce Dits, Maria del Pilar Diz Taín, M. Dómine Gómez, Timothy Dorius, Daphne W. Dumoulin, M. Duruisseaux, Keith D. Eaton, Emilio Esteban González, Devon Evans, Martin Faehling, Nicholas Farrell, Trevor Feinstein, E. Felip Font, M.R. García Campelo, Edward B. Garon, María Pilar Garrido López, Paul Germonpré, Todd Gersten, María González Cao, Srivalli Gopaluni, Laurent Greillier, Francesco Grossi, Florian Guisier, Sarada Gurubhagavatula, Vanesa Gutiérrez Calderón, David Hakimian, Richard D. Hall, Desirée Hao, Ronald Harris, Sayed M.S. Hashemi, Kai He, Lizza Hendriks, Chao Huang, Emad Ibrahim, Sharad Jain, Melissa L. Johnson, B. J. P. Jones, Monte Jones, Óscar Juan, Rosalyn A. Juergens, Courèche Kaderbhaï, Elisabeth A. Kastelijn, Roger Keresztes, Ebenezer A. Kio, Konrad Kokowski, Kartik Konduri, Swati Kulkarni, Jonas Kuon ほか 84 名 - Annals of Oncology 2023 被引用: 93

  19. Detection of NRG1 Gene Fusions in Solid Tumors

    著者: Sushma Jonna, Rebecca Feldman, Jeffrey Swensen, Zoran Gatalica, W. Michael Korn, Hossein Borghaei, C. Patrick, Jorgé Nieva, Alexander I. Spira, Ari M. Vanderwalde, Antoinette J. Wozniak, Edward S. Kim, Stephen V. Liu - Clinical Cancer Research 2019 被引用: 229

  20. The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials

    著者: written on behalf of AME Lung Cancer Collaborative Group, Yangyang Xu, Bing Wan, Xi Chen, Ping Zhan, Yuan Zhao, Tianli Zhang, Hongbing Liu, Muhammad Zubair Afzal, Said Dermime, Steven N. Hochwald, Paul Hofman, Hossein Borghaei, Dang Lin, Tangfeng Lv, Yong‐Seok Song - Translational Lung Cancer Research 2019 被引用: 169

  21. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

    著者: Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam, Leora Horn, Javier de Castro, Adam Płużański, Marco Angelo Burgio, Marina Chiara Garassino, Laura Q.M. Chow, Scott Gettinger, Lucio Crinò, David Planchard, Charles Butts, Alexander Drilon, Joanna Wójcik-Tomaszewska, Gregory A. Otterson, Shruti Agrawal, Ang Li, John R. Penrod, Julie R. Brahmer - The Lancet Oncology 2019 被引用: 365

  22. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

    著者: Scott Gettinger, Naiyer A. Rizvi, Laura Q.M. Chow, Hossein Borghaei, Julie R. Brahmer, Neal Ready, David E. Gerber, Frances A. Shepherd, Scott Antonia, Jonathan W. Goldman, Rosalyn A. Juergens, Scott A. Laurie, Faith E. Nathan, Yun Shen, Christopher Harbison, Matthew D. Hellmann - Journal of Clinical Oncology 2016 被引用: 498

  23. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

    著者: Patrick M. Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs, Thomas J. Purcell, Rafael Santana-Dávila, Arkadiusz Z. Dudek, Hossein Borghaei, Mara Lanis, Zineb Belcaid, Kellie N. Smith, Archana Balan, James R. White, Christopher Cherry, I.K. Ashok Sivakumar, Xiaoshan M. Shao, Hok Yee Chan, Dipika Singh, Sampriti Thapa, Peter B. Illei, Drew M. Pardoll, Rachel Karchin, Victor E. Velculescu, Julie R. Brahmer, Suresh S. Ramalingam - Nature Medicine 2021 被引用: 128

  24. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

    著者: David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, M.C. Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry Jahan, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Rogério Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M.W. Pisters, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, James Stevenson, Steven Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2016 被引用: 738